Clopidogrel Ratiopharm
Antiplatelet Agent for Prevention of Blood Clots
Quick Facts About Clopidogrel Ratiopharm
Key Takeaways About Clopidogrel Ratiopharm
- Proven cardiovascular protection: Clopidogrel reduces the risk of heart attack, ischaemic stroke, and vascular death in patients with established atherosclerotic disease, as demonstrated in the landmark CAPRIE trial
- Essential after stent placement: Used with aspirin as dual antiplatelet therapy (DAPT) for 6–12 months after coronary stenting to prevent stent thrombosis
- Avoid omeprazole/esomeprazole: These proton pump inhibitors significantly reduce clopidogrel’s effectiveness by inhibiting the CYP2C19 enzyme needed for activation
- Increased bleeding risk: As an antiplatelet agent, clopidogrel increases the risk of bleeding. Inform all healthcare providers and dentists that you take this medicine
- Do not stop without medical advice: Premature discontinuation, especially after stent placement, can lead to life-threatening stent thrombosis
What Is Clopidogrel Ratiopharm and What Is It Used For?
Clopidogrel Ratiopharm contains the active substance clopidogrel, an antiplatelet medicine that prevents blood platelets from sticking together to form clots. It is prescribed to reduce the risk of atherothrombotic events – including heart attack, ischaemic stroke, and vascular death – in patients with established cardiovascular disease.
Clopidogrel belongs to the thienopyridine class of antiplatelet drugs and works by irreversibly blocking the P2Y12 adenosine diphosphate (ADP) receptor on the surface of blood platelets. When this receptor is blocked, platelets are less able to aggregate (clump together), which significantly reduces the risk of forming dangerous blood clots within arteries. This mechanism is distinct from aspirin, which inhibits the cyclooxygenase (COX) pathway, and the two drugs are often used together for enhanced protection.
Clopidogrel Ratiopharm is a generic formulation of clopidogrel, bioequivalent to the original brand Plavix. It is manufactured by Ratiopharm (part of the Teva Pharmaceutical group) and is available as 75 mg film-coated tablets. The European Medicines Agency (EMA) and other regulatory authorities have approved clopidogrel for use in multiple clinical settings, based on extensive clinical trial evidence involving over 100,000 patients.
The primary approved indications for clopidogrel include:
- Recent myocardial infarction (heart attack): Starting from a few days up to 35 days after the event, to prevent recurrence
- Recent ischaemic stroke: Starting from 7 days up to 6 months after the event, to reduce the risk of further strokes
- Established peripheral arterial disease (PAD): In patients with symptomatic peripheral vascular disease, to reduce atherothrombotic events
- Acute coronary syndrome (ACS): In combination with aspirin for non-ST-segment elevation ACS (unstable angina or non-Q-wave myocardial infarction) and ST-segment elevation myocardial infarction (STEMI) in patients eligible for thrombolytic therapy
- Atrial fibrillation: In patients with atrial fibrillation who have at least one risk factor for vascular events and who cannot take oral anticoagulants, clopidogrel may be used with aspirin
The clinical evidence supporting clopidogrel is extensive. The CAPRIE trial (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events), which enrolled 19,185 patients, demonstrated that clopidogrel 75 mg daily was superior to aspirin 325 mg daily in reducing the combined risk of ischaemic stroke, myocardial infarction, or vascular death (relative risk reduction of 8.7%). The CURE trial (Clopidogrel in Unstable Angina to Prevent Recurrent Events) subsequently showed that adding clopidogrel to aspirin in acute coronary syndromes reduced cardiovascular death, myocardial infarction, and stroke by 20% compared to aspirin alone.
What Should You Know Before Taking Clopidogrel Ratiopharm?
Before starting clopidogrel, it is essential to inform your doctor about any bleeding disorders, planned surgeries, liver problems, or allergies. Certain medications – particularly some proton pump inhibitors – can significantly reduce clopidogrel’s effectiveness and may need to be avoided or substituted.
Contraindications
You should not take Clopidogrel Ratiopharm if any of the following apply to you:
- Allergy to clopidogrel: If you are allergic to clopidogrel or any of the other ingredients in the tablets (including lactose, microcrystalline cellulose, hydroxypropylcellulose, hydrogenated castor oil, and the film-coating components)
- Active pathological bleeding: If you currently have active bleeding such as a peptic ulcer (stomach or duodenal ulcer) or intracranial haemorrhage (bleeding inside the skull)
- Severe liver impairment: If you have severe liver disease that may affect blood clotting
If you have previously experienced a condition called thrombotic thrombocytopenic purpura (TTP) after taking clopidogrel or another thienopyridine (such as ticlopidine), you should not take this medicine. TTP is a rare but serious condition characterised by widespread blood clotting in small vessels, low platelet count, and organ damage.
Warnings and Precautions
Talk to your doctor or pharmacist before taking clopidogrel if any of the following situations apply:
- Bleeding risk: If you have an increased risk of bleeding due to trauma, surgery (including dental procedures), or other medical conditions. You should stop clopidogrel at least 5–7 days before planned surgery unless the antiplatelet effect is specifically desired
- Recent stroke: If you have had an ischaemic stroke within the last 7 days (clopidogrel is not recommended in this early period)
- Kidney impairment: Limited experience exists in patients with severe renal impairment; use with caution
- Liver impairment: Clopidogrel requires hepatic metabolism for activation; moderate liver impairment may affect the drug’s efficacy
- CYP2C19 poor metaboliser status: Approximately 2–14% of the population (depending on ethnicity) are poor metabolisers of CYP2C19. These individuals have significantly reduced conversion of clopidogrel to its active form, resulting in diminished antiplatelet effect and potentially increased risk of cardiovascular events. Pharmacogenomic testing is available and may be recommended in certain clinical situations
If you have had a coronary stent placed, premature discontinuation of clopidogrel significantly increases the risk of stent thrombosis, which can be fatal. Never stop taking clopidogrel without first consulting your cardiologist, even if you experience side effects. If you need to undergo surgery, discuss with both your surgeon and cardiologist about the risks of stopping versus continuing the medication.
Pregnancy and Breastfeeding
Clopidogrel should preferably not be used during pregnancy. Animal studies have not shown direct harmful effects on the developing foetus, but there are no adequate and well-controlled studies in pregnant women. As a precautionary measure, it is recommended to avoid clopidogrel during pregnancy unless the clinical benefit clearly outweighs the potential risk to the foetus.
It is not known whether clopidogrel or its metabolites are excreted in human breast milk. Studies in rats have shown that clopidogrel and its metabolites are excreted in milk. As a precaution, breastfeeding should be discontinued during treatment with clopidogrel. If antiplatelet therapy is essential during breastfeeding, your doctor may consider aspirin as an alternative, as more safety data are available for aspirin use during lactation.
If you are pregnant, planning to become pregnant, or breastfeeding, consult your doctor before taking Clopidogrel Ratiopharm. Your doctor will weigh the benefits against the risks and may suggest an alternative treatment strategy if appropriate.
How Does Clopidogrel Ratiopharm Interact with Other Drugs?
Clopidogrel has several clinically significant drug interactions. The most important is with certain proton pump inhibitors (omeprazole and esomeprazole), which reduce clopidogrel’s activation. Drugs that increase bleeding risk, such as warfarin and NSAIDs, require careful monitoring when used concurrently.
Clopidogrel is a prodrug that requires activation by hepatic cytochrome P450 enzymes, particularly CYP2C19. Any drug that inhibits or induces these enzymes can alter clopidogrel’s effectiveness. Additionally, because clopidogrel inhibits platelet aggregation, combining it with other anticoagulants or antiplatelet agents increases the risk of bleeding.
Major Interactions
| Drug / Class | Interaction Type | Clinical Significance | Recommendation |
|---|---|---|---|
| Omeprazole, Esomeprazole | CYP2C19 inhibition | Reduces active metabolite by 25–50%, diminishing antiplatelet effect | Avoid combination. Use pantoprazole or lansoprazole if PPI needed |
| Warfarin, other oral anticoagulants | Additive bleeding risk | Significantly increased risk of major haemorrhage | Avoid combination unless specifically indicated; monitor closely |
| NSAIDs (ibuprofen, naproxen) | Additive bleeding risk + GI toxicity | Increased risk of gastrointestinal and other bleeding | Use with caution; consider gastroprotection with pantoprazole |
| SSRIs (fluoxetine, fluvoxamine) | Additive bleeding + CYP2C19 inhibition | Increased bleeding risk; some SSRIs may also reduce clopidogrel activation | Monitor for bleeding; consider SSRI alternatives (sertraline, citalopram) |
| Heparin, LMWH | Additive bleeding risk | Substantially increased haemorrhagic risk during concurrent use | Use only under specialist supervision; monitor aPTT and clinical signs |
| Thrombolytics (alteplase, tenecteplase) | Additive bleeding risk | High risk of major bleeding | Specialist use only in acute MI setting; benefits generally outweigh risks |
| Repaglinide | CYP2C8 inhibition by clopidogrel metabolite | Increased repaglinide exposure (up to 5-fold), risk of hypoglycaemia | Avoid combination or use reduced repaglinide dose with glucose monitoring |
Minor Interactions
Several other medications may have minor or theoretical interactions with clopidogrel. Aspirin, when used at low doses (75–100 mg daily) as part of prescribed dual antiplatelet therapy, is an intentional and well-studied combination that increases bleeding risk modestly but provides substantial cardiovascular benefit. Your doctor has already accounted for this risk when prescribing DAPT.
Grapefruit juice has been studied for its effect on clopidogrel metabolism. While grapefruit inhibits CYP3A4 (which plays a role in clopidogrel activation), the clinical significance of this interaction appears minimal, as CYP2C19 is the primary enzyme involved. Nevertheless, some clinicians recommend moderation in grapefruit consumption during clopidogrel therapy.
Morphine and other opioids can delay gastric absorption of oral medications, including clopidogrel. This is particularly relevant in the acute setting of myocardial infarction, where opioids are commonly administered for pain relief. Studies have shown that morphine can delay the onset of clopidogrel’s antiplatelet effect by 1–2 hours. In acute coronary syndrome, some guidelines now recommend considering crushed clopidogrel tablets or alternative P2Y12 inhibitors (such as ticagrelor or prasugrel) when opioids are co-administered.
What Is the Correct Dosage of Clopidogrel Ratiopharm?
The standard maintenance dose of clopidogrel is 75 mg once daily, taken with or without food. In acute coronary syndromes, a loading dose of 300–600 mg may be given initially under medical supervision to achieve rapid platelet inhibition.
Adults
Standard Maintenance Therapy
The recommended dose is 75 mg once daily, taken at the same time each day, with or without food. Treatment duration varies depending on the indication:
- After myocardial infarction: Start within a few days to 35 days after the event; typical duration is 12 months or longer as determined by your doctor
- After ischaemic stroke: Start from 7 days to 6 months after the event
- Peripheral arterial disease: Long-term use as directed by your doctor
Acute Coronary Syndrome (with aspirin)
Treatment typically begins with a loading dose of 300 mg (four 75 mg tablets taken at once), followed by 75 mg once daily in combination with aspirin (75–100 mg daily). In some centres, particularly for patients undergoing percutaneous coronary intervention (PCI), a higher loading dose of 600 mg may be used to achieve more rapid platelet inhibition.
Duration of dual antiplatelet therapy (DAPT) after stent placement:
- Drug-eluting stent: Typically 6–12 months
- Bare-metal stent: Typically 1–6 months
- After acute coronary syndrome: At least 12 months regardless of stent type
ST-Segment Elevation Myocardial Infarction (STEMI)
A loading dose of 300 mg followed by 75 mg once daily in combination with aspirin, with or without thrombolytics. Treatment should continue for at least 4 weeks (based on the CLARITY and COMMIT trials).
Children and Adolescents
Clopidogrel is generally not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of clopidogrel in the paediatric population have not been established. The CLARINET trial, which evaluated clopidogrel in neonates and infants with cyanotic congenital heart disease, did not demonstrate a benefit over placebo. In rare cases where antiplatelet therapy is needed in children (such as after Kawasaki disease or certain cardiac procedures), the treating paediatric cardiologist will determine the appropriate therapy and dose.
Elderly Patients
No dose adjustment is required for elderly patients. The standard dose of 75 mg daily is used regardless of age. However, elderly patients are at inherently higher risk of both cardiovascular events and bleeding complications. In the CAPRIE and CURE trials, patients aged 65 and older demonstrated similar efficacy and safety profiles to younger patients, though the absolute rate of bleeding was higher. Close monitoring is advisable, particularly in patients over 75 years of age or those with additional bleeding risk factors such as low body weight, renal impairment, or concurrent use of other antithrombotic agents.
Missed Dose
If you forget to take a dose of Clopidogrel Ratiopharm:
- Less than 12 hours late: Take the missed dose as soon as you remember, then continue with your regular schedule
- More than 12 hours late: Skip the missed dose and take the next dose at the usual time
- Never take a double dose to make up for a forgotten dose
Clopidogrel’s antiplatelet effect is irreversible and cumulative, so a single missed dose is unlikely to cause an immediate loss of protection. However, consistent daily dosing is important for maintaining steady platelet inhibition. If you miss doses frequently, speak to your doctor or pharmacist about strategies to improve adherence.
Overdose
Overdose of clopidogrel may lead to prolonged bleeding time and subsequent bleeding complications. There is no specific antidote for clopidogrel. If excessive bleeding occurs, platelet transfusion may be considered to restore platelet function, as the drug’s effect is irreversible on exposed platelets. In the event of a suspected overdose, contact your local poison control centre or emergency medical services immediately.
In clinical studies, single doses of clopidogrel up to 600 mg have been administered without major adverse effects. Symptoms of overdose are expected to include exaggerated pharmacological effects, primarily an increased tendency to bleed.
What Are the Side Effects of Clopidogrel Ratiopharm?
The most common side effects of clopidogrel are bleeding-related, including bruising and nosebleeds. Most side effects are mild to moderate. Seek immediate medical attention for signs of severe bleeding, unusual bruising, or symptoms of thrombotic thrombocytopenic purpura (TTP) such as fever, confusion, and dark urine.
Like all medicines, clopidogrel can cause side effects, although not everybody gets them. The side effects are grouped below by frequency, based on data from large clinical trials and post-marketing surveillance. Bleeding is the most common adverse reaction and can occur at any site in the body. The risk of bleeding increases when clopidogrel is used in combination with aspirin or other antithrombotic agents.
Common (affects 1 to 10 in every 100 people)
- Bruising (haematoma)
- Nosebleeds (epistaxis)
- Gastrointestinal bleeding (stomach or intestinal)
- Diarrhoea
- Abdominal pain
- Indigestion (dyspepsia)
- Bleeding at puncture sites (e.g., after blood tests or injections)
Uncommon (affects 1 to 10 in every 1,000 people)
- Headache
- Dizziness and paraesthesia (tingling or numbness)
- Gastric ulcer, duodenal ulcer
- Nausea, vomiting, flatulence, constipation
- Skin rash, pruritus (itching)
- Blood in the urine (haematuria)
- Prolonged bleeding time
- Decreased platelet count (thrombocytopenia)
- Decreased white blood cell count (leucopenia), decreased neutrophils (neutropenia)
- Eye bleeding (conjunctival, ocular, retinal haemorrhage)
Rare (affects 1 to 10 in every 10,000 people)
- Severe thrombocytopenia (platelet count below 30,000/mm³)
- Vertigo
- Retroperitoneal haemorrhage (bleeding behind the abdominal cavity)
- Intracranial haemorrhage (bleeding inside the skull)
- Musculoskeletal bleeding (haemarthrosis)
Very Rare / Post-Marketing Reports (affects fewer than 1 in 10,000 people)
- Thrombotic thrombocytopenic purpura (TTP) – a serious condition requiring urgent treatment
- Aplastic anaemia, pancytopenia, agranulocytosis
- Severe liver disorders (hepatitis, acute liver failure)
- Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme)
- Angioedema, anaphylactic reactions
- Vasculitis (inflammation of blood vessels)
- Interstitial pneumonitis, eosinophilic pneumonia
- Taste disturbances (ageusia)
- Serum sickness-like reactions
- Drug-induced liver injury with cholestatic jaundice
Contact your doctor or go to the emergency department immediately if you experience any of the following:
- Signs of severe bleeding: blood in your stools (black or tarry), blood in your urine (red or dark brown), vomiting blood or material that looks like coffee grounds, unexplained severe nosebleeds that do not stop
- Signs of TTP: unexplained fever, extreme fatigue, confusion, dark-coloured urine, yellowing of the skin or eyes, purple spots on the skin
- Signs of severe allergic reaction: swelling of the face, lips, or throat, difficulty breathing, severe rash or hives
- Signs of stroke: sudden numbness or weakness on one side, difficulty speaking, sudden severe headache, vision problems
How Should You Store Clopidogrel Ratiopharm?
Store Clopidogrel Ratiopharm at room temperature below 30°C, in the original packaging to protect from moisture and light. Keep out of reach and sight of children.
Proper storage of medications is essential to maintain their effectiveness and safety throughout the shelf life. Follow these guidelines for storing Clopidogrel Ratiopharm:
- Temperature: Store below 30°C (86°F). Do not refrigerate or freeze the tablets
- Moisture protection: Keep the tablets in their original blister packaging or container until you are ready to take them. This protects them from humidity
- Light protection: Avoid exposing the tablets to direct sunlight. Store in the original carton
- Child safety: Store in a secure location out of the reach and sight of children. Consider using a locked medicine cabinet
- Expiry date: Do not use Clopidogrel Ratiopharm after the expiry date printed on the blister and carton. The expiry date refers to the last day of that month
Do not dispose of medicines in household waste or wastewater. Ask your pharmacist about how to dispose of medicines you no longer use. These measures help to protect the environment. If you notice any visible changes in the appearance of the tablets (such as discolouration, crumbling, or an unusual odour), do not take them and consult your pharmacist.
What Does Clopidogrel Ratiopharm Contain?
Each film-coated tablet contains 75 mg of clopidogrel (as clopidogrel hydrogen sulphate, equivalent to 97.875 mg of clopidogrel hydrogen sulphate). The tablets also contain several inactive ingredients (excipients) that help form and preserve the tablet.
The complete composition of Clopidogrel Ratiopharm 75 mg film-coated tablets is as follows:
Active substance:
- Clopidogrel 75 mg (as clopidogrel hydrogen sulphate)
Tablet core excipients:
- Lactose monohydrate
- Microcrystalline cellulose
- Hydroxypropylcellulose (low substituted)
- Hydrogenated castor oil
Film-coating:
- Hypromellose (hydroxypropyl methylcellulose)
- Titanium dioxide (E171)
- Iron oxide red (E172)
- Triacetin
- Carnauba wax
Clopidogrel Ratiopharm tablets are pink, round, biconvex, and film-coated. They are supplied in blister packs. Note that the tablets contain lactose – if you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. The amount of lactose per tablet is small but should be considered by patients with severe lactose intolerance or galactose malabsorption.
Frequently Asked Questions About Clopidogrel Ratiopharm
Clopidogrel Ratiopharm is an antiplatelet medicine used to prevent blood clots (atherothrombotic events) in adults who have experienced a heart attack (myocardial infarction), ischaemic stroke, or have established peripheral arterial disease. It is also used together with aspirin in patients with acute coronary syndrome (unstable angina or heart attack), including those who have had a coronary stent placed. By preventing platelets from clumping together, it reduces the risk of further cardiovascular events.
The most common side effects of clopidogrel are bleeding-related events, including nosebleeds (epistaxis), bruising (haematoma), gastrointestinal bleeding, and bleeding at puncture sites. Other common side effects include diarrhoea, abdominal pain, indigestion (dyspepsia), and headache. Most side effects are mild to moderate. Seek immediate medical attention if you experience signs of severe bleeding, such as black tarry stools, blood in urine, or unusual prolonged bleeding.
Yes, clopidogrel is commonly prescribed together with low-dose aspirin (75–100 mg daily) as dual antiplatelet therapy (DAPT). This combination is the standard of care after acute coronary syndromes and coronary stent placement, typically continued for 6 to 12 months. While the combination increases bleeding risk compared to either drug alone, the cardiovascular benefits in these specific clinical settings significantly outweigh the risks. Always follow your doctor’s instructions regarding duration of dual therapy.
Omeprazole and esomeprazole inhibit the CYP2C19 enzyme, which is essential for converting clopidogrel into its active antiplatelet form. This interaction can reduce clopidogrel’s effectiveness by 25–50%, potentially increasing the risk of cardiovascular events. The FDA and EMA have both issued warnings about this interaction. If you need a proton pump inhibitor for acid reflux or stomach protection while on clopidogrel, your doctor may prescribe pantoprazole or lansoprazole instead, as these have a weaker interaction with CYP2C19.
After coronary stent placement, dual antiplatelet therapy (clopidogrel plus aspirin) is typically recommended for 6 to 12 months, depending on the type of stent, the clinical indication, and your individual bleeding risk. Patients with drug-eluting stents generally require longer treatment than those with bare-metal stents. After an acute coronary syndrome, at least 12 months of DAPT is usually recommended regardless of stent type. Your cardiologist may consider shorter or longer durations based on your specific risk profile. Never stop clopidogrel without consulting your cardiologist, as premature discontinuation significantly increases the risk of stent thrombosis.
If you miss a dose of clopidogrel, take it as soon as you remember if less than 12 hours have passed. If more than 12 hours have elapsed, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a forgotten one. A single missed dose is unlikely to cause an immediate problem because clopidogrel’s antiplatelet effect is cumulative and lasts for the lifetime of the platelet (7–10 days). However, consistent daily dosing is important for maintaining optimal protection. If you frequently forget doses, consider setting a daily alarm or using a pill organiser.
References
- CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet. 1996;348(9038):1329-1339. doi:10.1016/S0140-6736(96)09457-3
- Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation (CURE trial). N Engl J Med. 2001;345(7):494-502. doi:10.1056/NEJMoa010746
- Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation (CLARITY-TIMI 28). N Engl J Med. 2005;352(12):1179-1189. doi:10.1056/NEJMoa050522
- Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial (COMMIT). The Lancet. 2005;366(9497):1607-1621. doi:10.1016/S0140-6736(05)67660-X
- European Medicines Agency (EMA). Clopidogrel Summary of Product Characteristics. Available at: https://www.ema.europa.eu. Accessed January 2026.
- Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191
- Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy. J Am Coll Cardiol. 2016;68(10):1082-1115. doi:10.1016/j.jacc.2016.03.513
- Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol. 2008;51(3):256-260. doi:10.1016/j.jacc.2007.06.064
- Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-375. doi:10.1056/NEJMoa0808227
- National Institute for Health and Care Excellence (NICE). Antiplatelet treatment. NICE Clinical Guideline. Available at: https://www.nice.org.uk. Accessed January 2026.
- World Health Organization (WHO). Model List of Essential Medicines – 23rd list, 2023. Geneva: WHO; 2023.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising specialists in cardiology, haematology, and clinical pharmacology. Our team follows strict editorial standards based on international medical guidelines, including the ESC, AHA/ACC, and WHO recommendations.
Content created by medical writers with expertise in cardiovascular pharmacology and evidence-based medicine. All clinical information is sourced from peer-reviewed journals, regulatory documents, and established treatment guidelines.
Independently reviewed by board-certified cardiologists and clinical pharmacologists. Reviewed for clinical accuracy, completeness, and adherence to current guidelines (ESC 2023, AHA/ACC 2016, NICE).
Evidence Level 1A – based on systematic reviews and meta-analyses of randomised controlled trials. References include landmark trials (CAPRIE, CURE, CLARITY, COMMIT) and current international guidelines.
No pharmaceutical company sponsorship, advertising, or commercial funding. All content is independently produced following the GRADE evidence framework and transparent editorial standards.